Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

yttrium Y 90-clivatuzumab tetraxetan

(IH-tree-um … KLY-vuh-TOO-zoo-mab teh-TRAK-seh-tan)

A substance being studied in the treatment of advanced pancreatic cancer. Yttrium Y 90-clivatuzumab tetraxetan contains a monoclonal antibody that binds to a protein called MUC-1, which is found on some pancreatic cancer cells. It also contains a radioactive substance called yttrium Y 90, which may help kill cancer cells. Yttrium Y 90-clivatuzumab tetraxetan is a type of radioimmunoconjugate. Also called yttrium Y 90-DOTA monoclonal antibody HuPAM4.

yttrium Y 90-clivatuzumab tetraxetan

Search NCI's Dictionary of Cancer Terms